 Lucid Diagnostics Inc. LUCD, -20.64 was jeered in its public debut, as the New York-based medical diagnostics technology companys stock opened on the Nasdaq 8.9 below its initial public offering price, and kept falling. The company raised 70.0 million, as it sold 5.0 million shares in its IPO, which priced overnight at 14 a share, at the bottom of the expected range of between 14 and 16 a share. 